まとめ
ミノキシジルは,心不全患者のための効果的な動脈血管拡張剤として有望であり,現在の治療法よりも毒性が潜在的に低い強力な長期的な効果を提供します.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 内科内科は,内科の内科である.
背景:
- 慢性心不全 (CHF) のための現在の血管拡張剤には限界があります:窒素は主に静脈拡張剤であり,プラゾシンは耐性を引き起こし,ヒドララジンには慢性毒性があります.
- CHFの最適な管理には,改善された安全性プロファイルを持つ効果的な動脈拡張剤が必要です.
研究 の 目的:
- 慢性左心房不全の患者におけるミノキシジルの単回投与による急性血液動力学的効果を評価する.
主な方法:
- 慢性左心房不全 (心筋不全または主心筋不全) を有する18人の患者は,単一の口服用ミネオキシジルの投与を受けた.
- 心拍数,平均動脈圧,心指数,全身血管抵抗,および様々な圧力を含む血液動力学的パラメータが測定されました.
- ピーク効果は5時間後に評価され,効果は投与後少なくとも8時間監視された.
主要な成果:
- ミノキシジルは心臓指数 (2.34〜2.95 l/min/m2) を著しく増加させ,全身血管抵抗 (19.6〜15.0単位) を低下させた.
- 心拍数 (85.4〜90.9bpm) のわずかな上昇と,平均動脈圧 (88.0〜84.9mm Hg) のわずかな低下が観察されました.
- ミノキシジルは右心房,肺動脈,または肺の圧力を有意に変化させず,その効果は少なくとも8時間持続しました.
結論:
- ミノキシジルは,ヒドララジンに似た,しかし潜在的により大きな効能と持続時間を持つ,心不全患者の効果的な動脈拡張剤として作用します.
- その長期的作用と比較的低い急性毒性は,ミノキシジルが心不全の管理に貴重な血管拡張剤である可能性があることを示唆しています.
- 心不全におけるミノキシジルの長期的な効果のさらなる評価は正当化されています.
さらに関連する動画
08:35Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
07:49A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
関連する概念動画
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
